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Edited by Jesus AvilaAbstract Activation of the neuronal receptor tyrosine kinase
ALK (anaplastic lymphoma kinase) promoted the neuron-like
diﬀerentiation of PC12 cells through speciﬁc activation of the
ERKMAP-kinase pathway. However, the nature of primary sig-
naling events initiated is still poorly documented. Here, we estab-
lished that Shc and FRS2 adaptors were recruited and
phosphorylated following antibody-based ALK activation. We
further demonstrated that Shc was recruited to the consensus
phosphotyrosine site NPTpY1507 and FRS2 was likely recruited
to a novel non-orthodox phosphotyrosine site within ALK. Final-
ly, we characterized a functional role for Shc and likely FRS2 in
ALK-dependant MAP-kinase activation and neuronal diﬀerenti-
ation of PC12 cells. These ﬁndings hence open attractive per-
spectives concerning speciﬁc characteristics of ALK in the
control of the mechanisms driving neuronal diﬀerentiation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neurite outgrowth1. Introduction
Anaplastic lymphoma kinase (ALK) is a 220 kDa receptor
tyrosine kinase (RTK) recently identiﬁed in human, mouse
and Drosophila [1–3]. ALK possesses a classical structure
shared with other RTKs, a large extracellular domain, a single
transmembrane domain and an intracellular domain contain-
ing the tyrosine kinase catalytic site and 18 tyrosine residues
forming potential sites of phosphorylation. The nature of its
cognate ligands in vertebrate is still a matter of debate [4–9].
The role of this receptor also still remains to be clearly identi-
ﬁed, however spatio-temporal expression studies [1,2,10]
strongly suggested that ALK could play an important role
in the development and function of the nervous system. In
agreement with this hypothesis, many studies demonstrated
that ALK activation promoted neuronal diﬀerentiation of
PC12 or neuroblastoma cell lines [8,9,11,12]. Analysis of the
signaling pathways pointed to an essential role of sustained*Corresponding author. Fax: +33 1 45 87 61 32.
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doi:10.1016/j.febslet.2007.01.039activation of the ERK MAP-kinase cascade. However, the
nature of the primary events initiated by ALK activation
and leading to MAP-kinase activation/PC12 cells diﬀerentia-
tion remains to be clariﬁed and can be a major clue to further
understand the mechanisms underlying the neuronal diﬀerenti-
ation processes.
Generally, following activation of RTKs, one of the primary
events leading to MAP-kinase activation is the direct recruit-
ment of a variety of intracellular modular proteins organized
in multimolecular signaling complexes [13]. The 80 kDa mem-
brane-anchored adaptor FRS2 (Fibroblast Receptor Sub-
strate-2) [14] has been described as an essential component
of the signaling complexes associated with the FGF (FGFR1)
[15,16], NGF (TrkA) [17], GDNF (RET) [18,19] and insulin
[20] receptors. Activation of FGFR1 or TrkA induces the acti-
vation of FRS2, which speciﬁcally participates to sustained
activation of MAP-kinase pathway and to neuronal diﬀerenti-
ation of PC12 cells [15,17,21–23]. Following autophosphoryla-
tion of TrkA [17] or RET [18,19] FRS2 classically binds to
speciﬁc phosphorylated tyrosine residues located within con-
served consensus sequences NPXpY or IENKLpY, respec-
tively. Surprisingly, FRS2 is constitutively bound to a
speciﬁc sequence in the juxtamembrane region of the FGFR1
that does not include any tyrosine residue: KSIPLRRQVTVS
[16]. Interestingly, FRS2 was found to directly bind TrkA at
the same phosphotyrosine residue (within the NPXpY site)
that binds another adaptor protein, Shc [17]. Shc (also named
ShcA) is expressed as three isoforms of about 46, 52 and
66 kDa. This competitive binding to TrkA suggested that
Shc and FRS2 could regulate a switch between proliferation
and diﬀerentiation of PC12 cells. Indeed, according to the
well-established model [24], Shc/Grb2/Ras pathway only trig-
gers transient activation of MAP-kinase pathway leading to
cell proliferation, whereas FRS2 signaling participates to sus-
tained activation of MAP-kinases leading to neuronal diﬀeren-
tiation.
Finally, FRS2 and Shc adaptors exhibited a similar expres-
sion pattern compared to ALK in several tissues during
development including the nervous system [25,26]. Therefore,
these data altogether led us to address in this report the ques-
tion of the potential involvement of FRS2 and Shc in rela-
tion to ERK MAP-kinase signaling and downstream
neuronal diﬀerentiation of PC12 cells induced by ALK acti-
vation. In order to control the activation of ALK in the ab-
sence of clearly established ligand(s), we took advantage of
monoclonal antibodies (mAbs) directed against the extracel-
lular domain of ALK which we recently generated and char-
acterized [9] and which presented all the characteristics of
activating antibodies.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmid constructions
The full-length human ALK cDNA as well as a construct coding for
a kinase-defective form in which the invariant lysine residue located in
the ATP-binding portion of the catalytic domain was changed to argi-
nine (this point mutation has been previously shown to completely in-
hibit the activation/phosphorylation of ALK [9,11,12]) was engineered
as previously described [11]. Mutation of tyrosine residues (Y) to phen-
ylalanine residues (F) was generated with the QuikChange site-directed
mutagenesis kit (Stratagene Europe, Amsterdam, The Netherlands)
within the four potential PTB binding sites present in the intracellular
domain of ALK: NPNY1096, NPTY1507, NVNY1584GY1586. Numbers
indicate the position of the Y residues in the ALK full length receptor.
ALK mutated forms coded by these constructs were respectively
named ALK-H Y1, ALK-H Y2 and ALK-H Y3-Y4. Constructs cod-
ing for the mutated forms ALK-H Y1-Y3-Y4 and ALK-H Y1-Y2-Y3-
Y4 were obtained by subcloning using appropriate restriction enzymes.
Mutagenesis was veriﬁed by sequencing (Genset, Paris, France). Con-
struct coding for the ALK receptor deleted of the 33 juxtamembrane
amino acids 1057–1089, named ALK-HDjuxt.mb, has been previously
described [28].
All generated constructs allowing the expression ALK-derived pro-
teins were linked to an HA tag at their C-terminal end.
The vector encoding FRS2 was kindly provided by J.K. Heath (CR-
UK Growth Factor Group, School of Biosciences, University of Bir-
mingham, UK) [27].
2.2. Cell culture and transfection
HEK 293 cells obtained from ATCC (Manassas, VA) were main-
tained in high glucose Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% foetal calf serum (Invitrogen) at 37 C in
atmosphere containing 5% CO2. Stably transfected cells [9] were cul-
tured continuously in the same medium complemented by 2 lg/ml
puromycin (Sigma). Parental HEK 293 cells were transiently transfec-
ted using calcium phosphate precipitation method as previously de-
scribed [9]. Cells plated at a density of 3 · 104 cells/cm2 were cultured
for 2 days, serum-deprived for 12–16 h, and then treated or not with
mAbs we previously described [9] directly added in the medium.
Rat pheochromocytoma (PC12) cells (kindly provided by T.Galli,
Institut Jacques Monod, Paris, France) were grown in a complete med-
ium (RPMI 1640, Invitrogen) supplemented with 10% horse serum
(HS) and 5% foetal calf serum (FCS) at 37 C in an atmosphere con-
taining 7.5% CO2. Cells were cultured in ﬂasks or plastic dishes coated
with collagen (1 lg/cm2). PC12 cells were electroporated as previously
described [9] and immediately transferred to fresh complete medium
for 1 day. Then, cells were serum starved in a low-serum medium
(1% HS without FCS) for 16 h before the addition of the mAbs.
2.3. Immunoprecipitation and immunoblotting analysis
Cell extracts were prepared by lysing the cells in a RIPA buﬀer
(10 mM NaPi buﬀer, pH 7.8, 60 mM NaCl, 1% Triton X-100, 0.5%
deoxycholic acid, 0.1% SDS, 10% glycerol, 25 mM b-glycerol phosphate,
50 mM sodium ﬂuoride, 2 mM sodium pyrophosphate, 1 mM sodium
orthovanadate and protease inhibitor mixture ‘‘complete’’, Roche)
and analysed by direct immunoblotting as previously described [9] or
subjected to immunoprecipitation (100 lg of total proteins) using the
1.5 lg of mouse anti-HA tag antibody (12CA5). Bound proteins were
visualized using the Odyssey Imaging System (LI-COR bioscience).
Antibodies and their sources were: mouse (12CA5) and rat (3F10)
monoclonal anti-HA (Roche Diagnostics, Meylan, France), mouse
anti-PY (4G10) and rabbit anti-ERK (Upstate Biotechnology, Lake Pla-
cid, NY), rabbit anti-PY (AB1599, Chemicon International, Temecula,
CA, USA), rabbit anti-FRS2 (H-91, Santa Cruz Biotechnology), rabbit
anti-Shc (Transduction laboratories), mouse anti-P-ERK (Sigma, Saint-
Quentin Fallavier, France). Rabbit anti-insulin receptor phosphospeciﬁc
antibody (pY/pY1162/1163, Biomol, Plymouth Meeting, PA) was used
for detection of tyrosine phosphorylated ALK due to the cross-reacting
properties of this antibody as previously discussed [9].2.4. Neurite outgrowth assay
Electroporated PC12 cells were treated at day 2 with the mAbs. At
day 4, cells were ﬁxed and processed for immunoﬂuorescence. Cells
were ﬁxed for 15 min at room temperature with pre-warmed 2% form-aldhehyde/30 mM sucrose and washed 3 times with PBS. Then cells
were permeabilized in 0.5% PBS-Triton X-100 for 5 min and washed
with 0.1 M PBS-glycine for 15 min. After 1 h of blocking in PBS con-
taining 1.5% BSA, cells were incubated in the same buﬀer with mono-
clonal rat anti-HA (3F10) antibody (0.9 lg/ml) to visualize cells
expressing ALK-H derived proteins. The cells were then washed 5
times with PBS before and after incubation with anti-rat IgG Alexa
488-conjugated secondary antibody (Molecular Probes, Leiden, The
Netherlands). Then cells were mounted in Mowiol 4-88 supplemented
with Hoechst 33258 nucleic acid stain (0.5lg/ml, Molecular Probes) to
visualize nuclei. Conventional ﬂuorescence microscopy was performed
on a Leica microscope (Roche Applied Science) equipped with a
MicroMax CCD camera (Princeton Instruments, Roper Scientiﬁc,
Trenton, NJ). Images were assembled using Adobe Photoshop soft-
ware. The Metamorph software was used (Roper Scientiﬁc) for quan-
tiﬁcation; 100 transfected cells were counted, and cells bearing neurites
longer than twice the diameter of the cell body were scored as diﬀeren-
tiated. The experiments were performed in triplicate.3. Results
3.1. Activation of ALK tyrosine kinase speciﬁcally induces
the recruitment and tyrosine phosphorylation of FRS2
and Shc adaptors
To address the question of the potential association of the
adaptor proteins FRS2 and Shc with ALK, we ﬁrst performed
co-immunoprecipitation experiments in HEK 293 cells stably
expressing the wild type human ALK receptor (ALK-H) or
its related kinase-defective form (dALK-H) [9] and further
transfected with the FRS2 vector. Cells were treated or not
during 15 min with 6 nM (1 lg/ml) of ALK-activating mouse
monoclonal antibody (mAb) 46 we previously developed [9].
Immunoblotting using rat anti-HA tag revealed that equal
amounts of ALK-H and dALK-H proteins were immunopre-
cipitated (Fig. 1A). According to our previous report, the weak
level of basal phosphorylation of both species of ALK-H (220-
kDa and 140-kDa) was strongly increased upon mAb 46 treat-
ment. By contrast, no phosphorylation was observed in cells
expressing the kinase-defective mutant (dALK-H). Therefore,
these data conﬁrmed that both basal and induced phosphory-
lation were a result of ALK-H intrinsic kinase activity, thus
validating the system of mAb-induced activation of the recep-
tor.
More interestingly, immunoblotting with anti-FRS2 and
anti-Shc antibodies (Fig. 1A) revealed that both the transfec-
ted FRS2 (80-kDa) and endogenous Shc (52-, and 46-kDa spe-
cies) adaptors were associated with ALK-H. Upon mAb 46
treatment, the adaptors are indeed more recruited and this is
strongly dependant to the phosphorylation state of the recep-
tor. In addition, co-immunoprecipitates of cells expressing
dALK-H did not display any anti-FRS2 or anti-Shc immu-
no-reactivity, thus revealing that ALK intrinsic kinase activity
was required for FRS2 and Shc association with ALK. Then,
in order to determine whether these two adaptors could be
activated in parallel to their association with ALK, immuno-
blotting experiment using anti-phosphotyrosine antibodies
was performed on whole-cell lysates displaying the same
amounts of FRS2, Shc, ALK-H or dALK-H proteins
(Fig. 1B). In the absence of mAb 46 treatment, FRS2 and
Shc adaptors exhibited basal levels of tyrosine phosphoryla-
tion that were signiﬁcantly increased in response to mAb 46
stimulation. These phosphorylations were due to ALK kinase
activity, as neither FRS2 nor Shc phosphorylation was ob-
served in cell extracts expressing the kinase defective form
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Fig. 1. mAb46-induced activation of ALK triggers FRS2 and Shc association with the receptor and their tyrosine phosphorylation. HEK 293 cells
stably transfected with the indicated ALK-H and dALK-H constructs were serum-starved for 16 h and then treated or not with activating mAb 46
(6 nM) during 15 minutes at 37 C. (A) Cells were lysed in RIPA buﬀer as described in Section 2 and 100 lg of proteins was then immunoprecipitated
using 1.5 lg of mouse anti-HA tag antibody (12CA5). Western blot analysis was performed using the rat anti-HA tag antibody (3F10), the rabbit
anti-insulin receptor phosphospeciﬁc antibody (see Section 2), anti-FRS2 antibody (H-91) or the anti-Shc antibody. (B) Cells were lysed in a RIPA
buﬀer and whole-cell lysates (10 lg) were submitted to Western blot analysis using the rat anti-HA tag antibody (3F10) (upper panel), the anti-FRS2
antibody (H-91) or the anti-Shc antibody (median panels). The blot was then reprobed with the rabbit anti-insulin receptor phosphospeciﬁc antibody
or phosphotyrosine (4G10 or rabbit) antibodies. Western blot analysis was also performed using the mouse anti-phosphoERK1/2 antibody and then
reprobed with the rabbit anti-panERK antibody (lower panel).
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(Fig. 1B) since sustained activation of MAP-kinase pathway
had been previously shown to be triggered by ALK activation
[8,9,11,12]. Immunoblotting using anti-phospho-ERK 1/2 anti-
bodies conﬁrmed that mAb 46 treatment increased the
phosphorylation of both the ERK 1 and 2 proteins, in a
long-lasting manner since it remained elevated for at least
1 h (data not shown). In addition, as no phosphorylation
was detected in cells expressing dALK-H, this conﬁrmed that
both basal and induced ERK phosphorylations were depen-
dent on ALK kinase activity.
3.2. Tyrosine 1507 of ALK is required for Shc association
with the receptor whereas any conventional PTB binding
site of ALK is required for FRS2 association
To determine which amino-acid motif of ALK could be in-
volved in Shc or FRS2 adaptors association to the receptor,
several mutants plasmid constructs derived from that encoding
the wild-type receptor ALK-H were engineered (represented in
Fig. 2A). First, since the juxtamembrane region of the FGFR1
has been previously described as the binding site of FRS2 [16],
we created a mutant allowing the expression of the ALK-H
protein deleted of its 33 juxtamembrane amino-acids (ALK-HDjuxt.mb.). Second, sequence analysis revealed that ALK
contains four putative phosphotyrosine-binding domain
(PTB) binding sites NXXpY. Since PTB domains of the
modular adaptors Shc and FRS2 could classically bind to spe-
ciﬁc phosphorylated tyrosine residues located within highly
conserved consensus sequences NPXpY of diﬀerent RTKs
[17–19], we created various point mutants of ALK-H by site-
directed mutagenesis, in which the diﬀerent tyrosines
(Y1096F: Y1; Y1507:Y2; Y1584:Y3; Y1586:Y4) were replaced
by phenylalanine residues. Then, parental HEK 293 cells were
transiently co-transfected with each of the various mutant con-
structs and with FRS2.
As shown in Fig. 2B, immunoblotting using anti-HA tag re-
vealed that comparable amounts of WT ALK-H and its re-
lated mutant proteins were immunoprecipitated. By contrast
to our previous results obtained with HEK cells stably express-
ing these proteins (see Fig. 1A and B), ALK-H and all the
other kinase active forms exhibited a strong basal level of
phosphorylation that was not increased upon 15 min of mAb
46 treatment. This basal phosphorylation has already been de-
scribed and discussed in previous studies [9,12] as a conse-
quence of protein overexpression in HEK cells transiently
transfected in comparison with cells stably expressing this
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Fig. 2. Tyrosine 1507 in the NPTY PTB binding site of ALK is required for Shc association with the receptor whereas no classical PTB binding site
of ALK is required for FRS2 association. (A) Schematic representation of the ALK-H mutant proteins: ALK-HDjuxt.mb. (ALK-H deleted of its 33
juxtamembrane amino-acids) and ALK-H Y1Y2Y3Y4 (point mutations: Y1096F Y1507F Y1584F Y1586F). ECD, extracellular domain; TM,
transmembrane domain; PTK, protein tyrosine kinase domain; HA, hemagglutinin tag. (B) Western blot analysis performed on cells transfected with
the ALK-H derived proteins after normalization of their levels of expression. HEK 293 cells were transiently transfected as described in Section 2
with the indicated ALK-H or ALK-H-derived mutant constructs and FRS2. Cells were serum-starved for 16 h and then treated or not with mAb 46
(6 nM) during 15 minutes at 37 C. Cells were lysed in a RIPA buﬀer and the lysates (10 lg) and 100 lg of proteins were then immunoprecipitated
using the 1.5 lg of mouse anti-HA tag antibody (12CA5). Western blot analysis was performed using the rat anti-HA tag (3F10), the rabbit anti-
insulin receptor phosphospeciﬁc, the anti-FRS2 (H-91) or the anti-Shc antibodies (upper panels). Whole-cell extracts were probed with the anti-
phosphoERK1/2 antibodies and then reprobed using anti-phosphotyrosine (4G10) and anti-panERK antibodies (lower panels).
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tant was indeed less phosphorylated than the diﬀerent mu-
tants, certainly relied either on a change of the structure of
its intracellular domain or on a impairment of the mobility
of the protein in the membrane. In addition, no ALK phos-
phorylation was observed in cells expressing the kinase-defec-
tive mutant (dALK-H), thus conﬁrming that both basal andinduced phosphorylation were a result of ALK intrinsic kinase
activity. Furthermore, mAb 46 treatment actually increased
ERK1/2 basal phosphorylation in all cell extracts and not in
those expressing the dALK-H form (Fig. 2B).
As described in Fig. 1A, Western blot analysis performed on
ALK-H and dALK-H co-immunoprecipitates (Fig. 2B) con-
ﬁrmed that both the FRS2 and Shc adaptors were associated
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quired. However, as a consequence of the high level of basal
phosphorylation of ALK, no discernible increase of FRS2
and Shc recruitment occurred upon mAb 46 treatment. More
surprisingly, FRS2 was also co-immunoprecipitated with all
the kinase active forms of ALK, but not by the kinase defective
form dALK-H. In addition, Western blot analysis using anti-
phosphotyrosine antibody performed on whole-cell lysates
expressing comparable amounts of FRS2 and ALK-H mutants
revealed that FRS2 was tyrosine phosphorylated in each case.
These data revealed that neither the juxtamembrane domain of
ALK-H nor the four tyrosine residues present in the NXXpY
motifs were required for FRS2 association with ALK. By con-
trast, Shc adaptor was not co-immunoprecipitated with the
ALK-H Y2 and ALK-H Y1Y2Y3Y4 mutants. This data dem-
onstrated that mutation of Y1507 abrogated Shc association
with ALK-H, revealing that this residue was speciﬁcally
responsible for Shc association to the receptor. Despite of its
low phosphorylation state, the ALK-HDjuxta.mb. mutant
could still eﬃciently associate with FRS2 and Shc adaptors,
and triggered ERK activation upon mAb treatment.3.3. MAP-kinase pathway activation and neuronal
diﬀerentiation of PC12 cells partially require Shc
association with ALK
To further investigate the functional outcomes of the associ-
ation of Shc and FRS2 with ALK, we tested their involvement
in MAP-kinase activation and subsequent neuron-like diﬀeren-
tiation of PC12 cells, two major eﬀects previously assigned to
ALK [9,11,12]. Whole-cell lysates of transiently transfected
PC12 cells expressing approximately identical amounts of
ALK-H derived proteins were subjected to Western blot anal-
ysis and ﬁrst assayed for ERK1/2 activation. Fig. 3A illus-
trated that ERK1/2 phosphorylation required ALK kinase
activity, thus conﬁrming in PC12 cells our ﬁrst results obtained
with HEK cells (see Fig. 1B). Indeed, mAb 46 treatment in-
duced the activation in cells expressing the ALK-H protein
and not in those expressing the kinase defective dALK-H. In
cells expressing the ALK-H Y2 and ALK-H Y1Y2Y3Y4 mu-
tants which previously were shown to display no association
with Shc, mAb 46 stimulation also induced ERK1/2 phosphor-
ylation, but to a signiﬁcantly weaker level compared to cells
expressing the WT ALK-H. This implied that Shc association
with ALK is required for a maximal ERK1/2 activation.
Therefore, Y1507 in ALK was essential for Shc association
with the receptor and partially required for subsequent
MAP-kinase phosphorylation in PC12 cells.
Then, in order to investigate the role of Shc adaptor in ALK-
dependent PC12 cells diﬀerentiation, we treated transfected
cells with 6 nM mAb 46 for two days and assayed for neurite
outgrowth. In the absence or presence of mAb 46, cells trans-
fected with the dALK-H construct or the empty vector alone
showed essentially a round shape and undiﬀerentiated
phenotype (data not shown). By contrast, cells expressing the
ALK-H protein (Fig. 3B) exhibited a signiﬁcant level of basal
diﬀerentiation (19%), displaying short and thin neurites. How-
ever, when treated with mAb 46, the percentage of these cells
extending neurites was greatly increased (63%) and they
displayed a much larger and spread cell body. Moreover, they
harboured thick neurite extensions (reaching several folds the
cell body size), which could be visible as early as the 12th hourof antibody treatment. These data conﬁrmed that ALK activa-
tion was required to induce PC12 cells diﬀerentiation
[8,9,11,12]. More interestingly, in the presence of mAb 46 the
percentage of cells expressing the ALK-H Y2 and ALK-H
Y1Y2Y3Y4 mutants that extend neurites was signiﬁcantly re-
duced (43%) compared to those expressing the WT ALK-H
protein (63%). This weaker diﬀerentiation level strongly paral-
leled the weaker level of MAP-kinases activation previously ob-
served in these cells (Fig. 3A). Altogether these data revealed
that Y1057 in ALK was essential for the recruitment and acti-
vation of Shc adaptor, leading to MAP-kinase pathway activa-
tion and subsequent neuronal diﬀerentiation of PC12 cells.4. Discussion
The purpose of the present study was to provide further ele-
ments to the understanding of the nature of the primary signal-
ing events initiated by activation of the receptor ALK. Indeed,
the role played by various modular adaptor proteins in ALK
signaling has been poorly documented so far. Only a few stud-
ies previously described that ALK activation resulted in the
association of insulin receptor substrate-1 (IRS-1), Shc,
c-Cbl, PLCc and the p85 subunit of PI3-kinase, subsequently
leading to tyrosine phosphorylation of IRS-1 and Shc [8].
Here, we ﬁrst corroborated the information that ALK activa-
tion triggered Shc association and its tyrosine phosphoryla-
tion. Furthermore, we characterized for the ﬁrst time the
precise phosphotyrosine residue (Y1507) of ALK that was crit-
ical for Shc association. Indeed, Y1507F (Y2) mutation has
been shown to totally abrogate Shc recruitment. This data is
in agreement with previous results obtained with the oncogenic
form of the receptor, NPM-ALK [29]. The Y2 mutation failed
to abrogate association of FRS2. These ﬁndings implicitly
demonstrated that Shc and FRS2 were not competing for asso-
ciation with ALK as such a mechanism had been previously
described with the NGF receptor (TrkA) [17]. This also implies
that diﬀerent sites of ALK could be required for respective Shc
and FRS2 association, thus disclosing a novel speciﬁc feature
of the receptor ALK.
Our studies also revealed for the ﬁrst time that FRS2 associ-
ation with ALK was dependent on the kinase activity of the
receptor. Therefore, this suggested that FRS2 was recruited
in a phosphotyrosine-dependent manner, as it had been previ-
ously shown with the receptors TrkA or RET [17–19] rather
being constitutively bound to the receptor as it had been pre-
viously shown with the FGFR1 receptor [16]. Indeed, yeast
two-hybrid protein–protein interaction assays revealed that
FRS2 was constitutively bound to a juxtamembrane region
of FGFR1, which do not contain any asparagine or tyrosine
residues. With the aim to determine which alternative binding
site was required for FRS2 association with ALK, we engi-
neered several mutants of the receptor. In agreement with
our hypothesis, we revealed that FRS2 association with
ALK did not require the presence of its juxtamembrane region.
Since our results suggested that the mechanism of FRS2 bind-
ing to ALK could be identical to that of TrkA or RET, we
engineered other mutants of ALK and further showed that
FRS2 association did not require any classical consensus
PTB-binding sequence of ALK, such as its four NXXpY mo-
tifs. As any other reported PTB-binding motif [30] has been de-
scribed in ALK amino-acid sequence, our results altogether
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medium at 37 C and treated or not with the mAb 46 (6 nM) for 15 minutes. Cells were then lysed in a RIPA buﬀer and the lysates (10 lg) were
submitted to Western blot analysis using the anti-HA tag (3F10) (upper panel), anti-phosphoERK1/2 or the anti-panERK antibodies (lower panels).
(B) Quantiﬁcation of the eﬀect of induced activation of the diﬀerent ALK-H or ALK-H-derived mutant proteins on neurite outgrowth. Transfected
PC12 cells were treated or not with the mAb 46 (6 nM) for 2 days, then ﬁxed, permeabilized and immunoﬂuorescence assay was performed. Cells
expressing the ALK-H derived proteins were labelled with the anti-HA-tag antibody (3F10) and cell nuclei were coloured with the nucleic acid stain
Hoechst 33258. Bar = 100 lm. Then, PC12 cells were submitted to neurite outgrowth assay as indicated in Section 2. The experiment was performed
in triplicate and values are expressed as the means ± S.E.M. (%).
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recruitment of FRS2 to a novel non-orthodox PTB-binding
site not related to those comprised within TrkA, RET, FGFR1
or any other protein.
Many studies focusing on the mechanisms of action trig-
gered by RTKs and leading to PC12 cells diﬀerentiation under-lined the critical role played by sustained activation of the
ERK MAP-kinase pathway in this process [31]. PC12 cells
can either diﬀerentiate from chromaﬃn-like cells to sympa-
thetic neuron-like cells when treated with various neurotrophic
factors such as NGF or FGF, or proliferate upon epidermal
growth factor (EGF) stimulation [32,33]. According to the
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kinase pathway induced by NGF or FGF was essential to pro-
mote PC12 cell diﬀerentiation whereas transient activation of
this pathway triggered proliferation of these cells. Our studies
revealed a functional role for Shc in ALK signaling, displaying
that association with ALK was partially required for ERK
activation and PC12 cells diﬀerentiation. We showed that
abrogation of ALK/Shc association in cells expressing the
mutants resulted in a complete lack of Shc recruitment. Shc
would be in turn unable to concomitantly recruit Grb2/Sos
proteins, resulting in the inhibition of Ras-dependent activa-
tion of ERK pathway we described here. However, it is note-
worthy that inhibition of MAP-kinases activation and PC12
cells diﬀerentiation triggered by ALK mutants was not com-
plete. This partial inhibition could be explained by the role
played by Shc regarding to the time-course of ERK activation.
Thus, one can propose that the remaining level of PC12 cells
diﬀerentiation might be a consequence of signals induced by
the recruitment of alternative proteins to ALK, which could
overcome the absence of Shc signaling and inhibition of the
transient phase of MAP-kinases activation. As mentioned
above, previous studies showed that IRS-1, PI3-kinase and
PLC-c were associated with ALK following its mAb-induced
activation [8]. However, our previous studies in the same sys-
tem based on the use of pharmacological inhibitors of PI3-ki-
nase and PLC-c demonstrated that both proteins were not
involved in ALK-dependent promotion of PC12 cells diﬀeren-
tiation [11,12]. Moreover, IRS-1 has been described as being
involved in the transient phase of MAP-kinases activation
and subsequently PC12 cells proliferation [34]. Therefore,
IRS-1 could act similarly to Shc, likely having only moderate
eﬀects on the sustained phase of MAP-kinases activation and
subsequent PC12 cells diﬀerentiation. However, FRS2 has
been reported as the preferential adaptor protein required
for prolonged activation of this ERK pathway and PC12 cells
diﬀerentiation [15,17,22,23]. Therefore, it seems reasonable to
assume that this novel ALK-associated adaptor can be a good
candidate for relaying the eﬀects triggered by the receptor.
However, since FRS2 binding site in ALK still remains a
conundrum, its identiﬁcation and further mutation studies will
be certainly informative on the speciﬁc role of FRS2 in ALK
signaling. Previous studies led in PC12 cells showed that a mu-
tant of Y490 of TrkA (the unique Shc and FRS2 binding site)
could neither activate the Ras signaling pathway nor promote
the neuronal diﬀerentiation of PC12 cells [35]. Thus, we could
expect that mutation of the diﬀerent binding sites of both Shc
and FRS2 in ALK will result in the complete lack of ERK 1/2
activation and PC12 cells diﬀerentiation.
In conclusion, our studies provided novel elements essential
for the understanding of the primary signaling events induced
by ALK activation, through the characterization of Shc and
FRS2 adaptors in ALK-dependant signaling leading to the dif-
ferentiation of PC12 cells. More particularly, we enlightened
some speciﬁc features of the receptor ALK regarding to the
mechanisms of adaptors recruitment. Finally, our results open
particularly attractive perspectives concerning speciﬁc charac-
teristics of the receptor ALK in the control of general mecha-
nisms driving neuronal diﬀerentiation.
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